SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI)

Abstract

BackgroundMIRAI (NCT01332994) investigated the early response to the IL-6 inhibitor tocilizumab (TCZ) within a homogeneous population of biological naïve patients (pts) with moderate/severe active RA who inadequately responded to traditional...